Shandong Runze "injection cephalosporine sodium" the second through a consistent evaluation

On January 7, the official website of the State Drug Administration showed that Shandong Runze Pharmaceutical injection cephalosporine sodium passed the consistent evaluation, becoming the second enterprise to evaluate the variety after Collum Pharmaceuticals.
5 specifications, 0.25mg/0.5mg/2mg/2.5mg/3mg.
cephalosporins are long-acting, broad-spectrum third-generation cephalosporin antibiotics, which are more active and β-endamide-negative bacteria than first- and second-generation cephalosporins, and have the advantages of long half-life, strong tissue penetration and small toxic side effects compared to other third-generation cephalosporins, and are now widely used in clinical practice to breathe. Departments of Medicine, Surgery, Obstetrics and Gynaecology, etc., have been recommended by the Guidelines for the Clinical Application of Antibacterial Drugs (2015), the Guidelines for the Diagnosis and Treatment of Celiac Infections in China (2019), the Code of Practice for the Diagnosis and Treatment of Sexual pneumonia in Children's Communities (2019), and the Guidelines for The Basic Rational Use of Adult Community Access pneumonia (2020).
sodium cephalosporine for the 2020 edition of the National Health Insurance Class A and the 2018 edition of the National Base Drug Catalog varieties, China's sales in 2019 reached 3.84 billion yuan.
PharmaGo database shows that the current variety of 20 enterprises, including Baiyunshan, Qilu, Stone Medicine, are in the consistent evaluation / as consistent evaluation declaration stage.
。